Breo® Ellipta™ Now Available in the U.S. for the Treatment of COPD
GlaxoSmithKline (GSK) and Theravance, Inc. have announced that Breo Ellipta, a once-daily prescription medicine for COPD, is now available in pharmacies throughout the U.S.
Breo Ellipta is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
“This new option for healthcare providers to prescribe is good news for the millions of people in the U.S. affected by COPD,” Jorge Bartolome, Senior Vice President of GSK Respiratory Business Unit in the U.S., says.
The Food and Drug Administration approved Breo Ellipta on May 10, 2013.